Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cognition Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CGTX
Nasdaq
8731
https://cogrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cognition Therapeutics Inc
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript
- Mar 27th, 2024 1:31 pm
Q4 2023 Cognition Therapeutics Inc Earnings Call
- Mar 27th, 2024 5:13 am
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
- Mar 26th, 2024 11:00 am
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
- Mar 15th, 2024 11:30 am
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
- Mar 14th, 2024 8:05 pm
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
- Mar 12th, 2024 12:16 am
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
- Mar 11th, 2024 8:05 pm
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
- Mar 6th, 2024 12:30 pm
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
- Feb 26th, 2024 12:30 pm
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
- Feb 6th, 2024 1:47 pm
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
- Jan 16th, 2024 1:51 pm
Cognition Therapeutics CEO Issues Letter to Shareholders
- Jan 4th, 2024 12:30 pm
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
- Nov 16th, 2023 12:30 pm
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
- Nov 15th, 2023 12:30 pm
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
- Nov 7th, 2023 12:30 pm
Cognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial Results
- Nov 3rd, 2023 10:00 am
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 2nd, 2023 11:30 am
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
- Oct 27th, 2023 11:30 am
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
- Oct 24th, 2023 8:30 pm
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
- Oct 16th, 2023 11:30 am
Scroll